enzastaurin has been researched along with Peritoneal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Benbrook, DM; Darcy, KM; De Geest, K; Godwin, AK; Hanjani, P; Hurteau, JA; Mannel, RS; Michelin, DP; Sill, MW; Usha, L | 1 |
2 trial(s) available for enzastaurin and Peritoneal Neoplasms
| Article | Year |
|---|---|
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Class I Phosphatidylinositol 3-Kinases; Female; Genes, p53; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Vascular Endothelial Growth Factor A | 2011 |